Nunaps

Nunaps develops digital therapeutics using AI and virtual reality technologies targeting neurological disorders, especially visual field defects after brain injury such as stroke. Its lead product(s) have demonstrated efficacy in improving vision-related function through perception training. The company’s VR-based software "VIVID Brain" received regulatory approval from the South Korean Ministry of Food and Drug Safety. Clinical studies show improvements in social functioning and vision-specific outcomes among chronic stroke patients with visual field deficits. The company continues to expand its pipeline into broader neurological indications using its proprietary digital health platforms.